Close Asset Management LTD Clovis Oncology, Inc. Transaction History

Close Asset Management LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 01, 2019	SELL	$12.81 - $25.67 $4,803 - $9,626	-375 Reduced 15.79%	2,000 $30,000
Q1 2019 May 10, 2019	BUY	$17.66 - $30.28 $5,298 - $9,084	300 Added 14.46%	2,375 $59,000
Q4 2018 Jan 28, 2019	BUY	$11.63 - $32.67 $5,233 - $14,701	450 Added 27.69%	2,075 $98,000
Q3 2018 Nov 09, 2018	SELL	$29.37 - $49.48 $5,139 - $8,659	-175 Reduced 9.72%	1,625 $48,000
Q4 2017 Feb 13, 2018	SELL	$57.69 - $84.58 $4,326 - $6,343	-75 Reduced 4.0%	1,800 $122,000
Q3 2017 Feb 13, 2018	BUY	$67.17 - $84.81 $100,755 - $127,215	1,500 Added 400.0%	1,875 $0
Q3 2017 Nov 14, 2017	SELL	$67.17 - $84.81 $100,755 - $127,215	-1,500 Reduced 80.0%	375 $31,000
Q2 2017 Feb 13, 2018	BUY	N/A	1,500 Added 400.0%	1,875 $176,000
Q2 2017 Nov 14, 2017	SELL	N/A	-2,625 Reduced 87.5%	375 $0
Q1 2017 Feb 13, 2018	BUY	N/A	2,400 Added 400.0%	3,000 $191,000
Q1 2017 Nov 14, 2017	BUY	N/A	600	600 $38,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Close Asset Management LTD, based on Form 13F filings with the SEC.

Stay updated on Close Asset Management LTD with notifications on news.